A Phase 2, 14-week Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily at Bedtime in Patients With Multisite Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)
Latest Information Update: 24 May 2024
At a glance
- Drugs Cyclobenzaprine (Primary)
- Indications Pain; Post acute COVID 19 syndrome
- Focus Proof of concept; Registrational; Therapeutic Use
- Acronyms PREVAIL
- Sponsors Tonix Pharmaceuticals Holding Corp
- 22 May 2024 According to a Tonix Pharmaceuticals Holding Corp media release, data from this study will be presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting being held May 28-31, 2024 at the Loews Miami Beach Hotel in Miami Beach, Fla.
- 12 Oct 2023 According to a Tonix Pharmaceuticals Holding Corp media release, enrollment in a Phase 2 proof-of-concept study has been completed, and topline results were reported in the third quarter of 2023.
- 05 Sep 2023 According to a Tonix Pharmaceuticals Holding Corp media release, the company expect to present full data in a peer-reviewed format and at upcoming medical conferences.